Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

X Wei

Showing results (861-870 of 938) with videos related to

Pageof 94
Sort By:
European Urology Oncology|November 15, 2024
Combined Fixed-duration Systemic Treatment and Metastasis-directed Radiotherapy for Oligometastatic Hormone-sensitive Prostate CancerPraful Ravi, Caiwei Zhong, Wanling Xie, et al.
BMC Medicine|February 3, 2017
What is the association of hypothyroidism with risks of cardiovascular events and mortality? A meta-analysis of 55 cohort studies involving 1,898,314 participantsYu Ning, Yun J Cheng, Li J Liu, et al.
JCO Precision Oncology|February 16, 2022
Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell CarcinomaBradley A McGregor, Wanling Xie, Elio Adib, et al.
Zhonghua Wai Ke Za Zhi [Chinese Journal of Surgery]|September 27, 2025
[One-year outcomes of a novel domestic transcatheter aortic valve system in severe aortic stenosis: a multicenter cohort study]Y H Li, J W Zhou, L Wei, et al.
The Prostate|March 19, 2025
Outcome of Subsequent Therapies After <sup>177</sup>Lu-Vipivotide Tetraxetan for Metastatic Castrate-Resistant Prostate Cancer: A Tertiary Cancer Center ExperienceMeryam Losee, Michael Kavanaugh, Mofei Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2021
Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving ResistanceRana R McKay, Lucia Kwak, Jett P Crowdis, et al.
Journal for Immunotherapy of Cancer|November 12, 2020
Prognostic significance and immune correlates of CD73 expression in renal cell carcinomaAbhishek Tripathi, Edwin Lin, Wanling Xie, et al.
Gynecologic Oncology|September 12, 2016
In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinomaMariam M AlHilli, Marc A Becker, S John Weroha, et al.
The Lancet. Oncology|June 3, 2023
Health-related quality of life and pain outcomes with [<sup>177</sup>Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trialKarim Fizazi, Ken Herrmann, Bernd J Krause, et al.
Zhonghua Yi Xue Za Zhi|April 15, 2019
[Mid-term multi-center outcomes of bilateral radial artery as conduits in coronary artery bypass grafting]X J Chen, B S Zheng, Y Zhang, et al.
Pageof 94

Showing results (861-870 of 938) with videos related to

Sort By:
Pageof 94
European Urology Oncology|November 15, 2024
Combined Fixed-duration Systemic Treatment and Metastasis-directed Radiotherapy for Oligometastatic Hormone-sensitive Prostate CancerPraful Ravi, Caiwei Zhong, Wanling Xie, et al.
BMC Medicine|February 3, 2017
What is the association of hypothyroidism with risks of cardiovascular events and mortality? A meta-analysis of 55 cohort studies involving 1,898,314 participantsYu Ning, Yun J Cheng, Li J Liu, et al.
JCO Precision Oncology|February 16, 2022
Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell CarcinomaBradley A McGregor, Wanling Xie, Elio Adib, et al.
Zhonghua Wai Ke Za Zhi [Chinese Journal of Surgery]|September 27, 2025
[One-year outcomes of a novel domestic transcatheter aortic valve system in severe aortic stenosis: a multicenter cohort study]Y H Li, J W Zhou, L Wei, et al.
The Prostate|March 19, 2025
Outcome of Subsequent Therapies After <sup>177</sup>Lu-Vipivotide Tetraxetan for Metastatic Castrate-Resistant Prostate Cancer: A Tertiary Cancer Center ExperienceMeryam Losee, Michael Kavanaugh, Mofei Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2021
Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving ResistanceRana R McKay, Lucia Kwak, Jett P Crowdis, et al.
Journal for Immunotherapy of Cancer|November 12, 2020
Prognostic significance and immune correlates of CD73 expression in renal cell carcinomaAbhishek Tripathi, Edwin Lin, Wanling Xie, et al.
Gynecologic Oncology|September 12, 2016
In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinomaMariam M AlHilli, Marc A Becker, S John Weroha, et al.
The Lancet. Oncology|June 3, 2023
Health-related quality of life and pain outcomes with [<sup>177</sup>Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trialKarim Fizazi, Ken Herrmann, Bernd J Krause, et al.
Zhonghua Yi Xue Za Zhi|April 15, 2019
[Mid-term multi-center outcomes of bilateral radial artery as conduits in coronary artery bypass grafting]X J Chen, B S Zheng, Y Zhang, et al.
Pageof 94